The efficacy of an IL-1α Vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction

Journal of Immunotherapy

Volumn 32, Issue 6, 2009, Pages 552-564

  Weiss, Tobias ^a   Vitacolonna, Mario ^a   Zöller, Margot ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Fibrosarcoma; IL 1; Mouse; Myeloid derived suppressor cells; Treg; Vaccine

Indexed keywords

3 METHYLCHOLANTHRENE; COMPLEMENTARY DNA; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIVE VACCINE; RETINOIC ACID; SALMONELLA TYPHIMURIUM INTERLEUKIN 1 ALPHA VACCINE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; INTERLEUKIN 1 RECEPTOR TYPE I;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNIZATION; CELL LYSATE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROPORATION; FIBROSARCOMA; KNOCKOUT MOUSE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SALMONELLA TYPHIMURIUM; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; SURVIVAL; T LYMPHOCYTE ACTIVATION; ACTIVE IMMUNIZATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; FIBROSARCOMA; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-1 TYPE I; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; TRETINOIN;

EID: 67651184038     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31819b7b9e     Document Type: Article

References (62)

1. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med. 2005;201:1355-1359.
2. Apte RN, Voronov E. Interleukin-1: a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol. 2002; 12:277-290.
3. Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett. 2006;580:6289-6294.
4. Swaan PW, Knoell DL, Helsper F, et al. Sequential processing of human ProIL-1beta by caspase-1 and subsequent folding determined by a combined in vitro and in silico approach. Pharm Res. 2001;18:1083-1090.
5. Sultana T, Wahab-Wahlgren A, Assmus M, et al. Expression and regulation of the prointerleukin-1alpha processing enzymes calpain I and II in the rat testis. Int J Androl. 2003;26: 37-45.
6. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006;25: 387-408.
7. Dvorkin T, Song X, Argov S, et al. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. J Leukoc Biol. 2006;80: 96-106.
8. Sutton C, Brereton C, Keogh B, et al. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006; 203:1685-1691.
9. Apte RN, Voronov E. Is interleukin-1 a good or bad "guy" in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222:222-241.
10. Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67: 1062-1071.
11. Saijo Y, Tanaka M, Miki M, et al. Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumorstromal interaction. J Immunol. 2002;169:469-475.
12. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008; 68:2561-2563.
13. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 2006;16:53-65.
14. Song X, Krelin Y, Dvorkin T, et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J Immunol. 2005; 175:8200-8208.
15. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284-290.
16. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev. 2006;212:8-27.
17. +Foxp3 T cells. J Leukoc Biol. 2008;84:480-487.
18. Yu P, Fu YX. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86:231-245.
19. Marhaba R, Nazarenko I, Knöfler D, et al. Opposing effects of fibrosarcoma cell-derived IL-1 alpha and IL-1 beta on immune response induction. Int J Cancer. 2008;123:134-145.
20. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63: 4441-4449.
21. Nefedova Y, Fishman M, Sherman S, et al. Mechanism of alltrans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 2007;67:11021-11028.
22. Dietrich G, Spreng S, Favre D, et al. Live attenuated bacteria as vectors to deliver plasmid DNA vaccines. Curr Opin Mol Ther. 2003;5:10-19.
23. Panthel K, Meinel KM, Sevil Domenech VE, et al. Salmonella type III-mediated heterologous antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol. 2008; 298:99-103.
24. Groisman EA, Ochman H. How Salmonella became a pathogen. Trends Microbiol. 1997;5:343-349.
25. Sirard JC, Niedergang F, Kraehenbuhl JP. Live attenuated Salmonella: a paradigm of mucosal vaccines. Immunol Rev. 1999;171:5-26.
26. Garmory HS, Leary SE, Griffin KF, et al. The use of live attenuated bacteria as a delivery system for heterologous antigens. J Drug Target. 2003;11:471-479.
27. Mollenkopf H, Dietrich G, Kaufmann SH. Intracellular bacteria as targets and carriers for vaccination. Biol Chem. 2001;382:521-532.
28. Darji A, Guzman CA, Gerstel B, et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 1997;91: 765-775.
29. Paglia P, Medina E, Arioli I, et al. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood. 1998;92:3172-3176.
30. Horai R, Asano M, Sudo K, et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med. 1998;187:1463-1475.
31. Hoiseth SK, Stocker BA. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981;291:238-239.
32. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell. 2007;12:192-199.
33. Berinstein N. Overview of therapeutic vaccination approaches for cancer. Semin Oncol. 2003;30:1-8.
34. Margolin K. Cytokine therapy in cancer. Expert Opin Biol Ther. 2008;8:1495-1505.
35. Dinarello CA. The paradox of pro-inflammatory cytokines in cancer. Cancer Metastasis Rev. 2006;25:307-313.
36. Lewis AM, Varghese S, Xu H, et al. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006;4:48.
37. Nazarenko I, Marhaba R, Reich E, et al. Tumorigenicity of IL-1alpha- and IL-1beta-deficient fibrosarcoma cells. Neoplasia. 2008;10:549-562.
38. Elaraj DM, Weinreich DM, Varghese S, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res. 2006;12:1088-1096.
39. Cullinan EB, Kwee L, Nunes P, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol. 1998;161:5614-5620.
40. Mochizuki DY, Eisenman JR, Conlon PJ, et al. Interleukin 1 regulates hematopoietic activity, a role previously ascribed to hemopoietin 1. Proc Natl Acad Sci U S A. 1987;84:5267-5271.
41. Neta R, Douches S, Oppenheim JJ. Interleukin 1 is a radioprotector. J Immunol. 1986;136:2483-2485.
42. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007;117:1155-1166.
43. Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-1144.
44. Weth R, Christ O, Stevanovic S, et al. Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination. Cancer Gene Ther. 2001;8:599-611.
45. Agorio C, Schreiber F, Sheppard M, et al. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med. 2007;9:416-423.
46. Chabalgoity JA, Baz A, Rial A, et al. The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev. 2007;18: 195-207.
47. Chirivi RG, Chiodoni C, Musiani P, et al. IL-1alpha genetransfected human melanoma cells increase tumor-cell adhesion to endothelial cells and their retention in the lung of nude mice. Int J Cancer. 1996;67:856-863.
48. McArthur JG, Raulet DH. CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4. J Exp Med. 1993;178:1645-1653.
49. Shibuya K, Robinson D, Zonin F, et al. IL-1 alpha and TNF-alpha are required for IL-12-induced development of Th1 cells producing high levels of IFN-gamma in BALB/c but not C57BL/6 mice. J Immunol. 1998;160:1708-1716.
50. Von Stebut E, Ehrchen JM, Belkaid Y, et al. Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med. 2003;198:191-199.
51. Su SB, Silver PB, Grajewski RS, et al. Essential role of the MyD88 pathway, but nonessential roles of TLRs 2, 4, and 9, in the adjuvant effect promoting Th1-mediated autoimmunity. J Immunol. 2005;175:6303-6310.
52. Veltri S, Smith JW II. Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects. Stem Cells. 1996;14:164-176.
53. Boraschi D, Nencioni L, Villa L, et al. In vivo stimulation and restoration of the immune response by the noninflammatory fragment 163-171 of human interleukin 1 beta. J Exp Med. 1988;168:675-686.
54. Mullerad J, Cohen S, Benharroch D, et al. Local delivery of IL-1 alpha polymeric microspheres for the immunotherapy of an experimental fibrosarcoma. Cancer Invest. 2003;21:720-728.
55. Rambaldi A, Torcia M, Bettoni S, et al. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood. 1991;78:3248-3253.
56. Konishi N, Miki C, Yoshida T, et al. Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology. 2005;68: 138-145.
57. Weinreich DM, Elaraj DM, Puhlmann M, et al. Effect of interleukin 1 receptor antagonist gene transduction on human melanoma xenografts in nude mice. Cancer Res. 2003;63: 5957-5961.
58. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov. 2004;3:330-339.
59. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA. 1995;92:1714-1718.
60. Smith DE, Hanna R, Della F, et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003;18:87-96.
61. Burger D, Chicheportiche R, Giri JG, et al. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 1995; 96:38-41.
62. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2003;9:47-52.